JG
CLVS

Jefferies Group’s Clovis Oncology, Inc. CLVS Stock Holding History

Jefferies Group’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-11,200
Closed -$53.8K – 2104
2020
Q4 		$53.8K Hold
11,200
– – ﹤0.01% 1488
2020
Q3 		$65K Hold
11,200
– – ﹤0.01% 1270
2020
Q2 		$76 Hold
11,200
– – ﹤0.01% 1138
2020
Q1 		$71K Sell
11,200
-155,500
-93% -$1.25M ﹤0.01% 1842
2019
Q4 		$1.74M Buy
166,700
+104,800
+169% +$762K 0.01% 1128
2019
Q3 		$243K Buy
61,900
+58,700
+1,834% +$475K ﹤0.01% 2270
2019
Q2 		$48K Sell
3,200
-73,000
-96% -$1.32M ﹤0.01% 2370
2019
Q1 		$1.89M Sell
76,200
-40,100
-34% -$1.01M 0.02% 943
2018
Q4 		$2.09M Buy
116,300
+67,000
+136% +$1.37M 0.02% 796
2018
Q3 		$1.45M Buy
+49,300
New +$1.91M 0.01% 1137
2017
Q3 		– Sell
-14,600
Closed -$1.37M – 2691
2017
Q2 		$1.37M Buy
14,600
+13,600
+1,360% +$832K 0.01% 1136
2017
Q1 		$64K Sell
1,000
-16,300
-94% -$991K ﹤0.01% 2168
2016
Q4 		$768K Sell
17,300
-49,000
-74% -$1.72M ﹤0.01% 1413
2016
Q3 		$2.39M Buy
66,300
+53,000
+398% +$1.14M 0.01% 852
2016
Q2 		$182K Sell
13,300
-3,500
-21% -$51.2K ﹤0.01% 1842
2016
Q1 		$323K Sell
16,800
-78,200
-82% -$1.66M ﹤0.01% 1642
2015
Q4 		$3.33M Buy
95,000
+81,200
+588% +$5.24M 0.02% 637
2015
Q3 		$1.27M Buy
+13,800
New +$1.19M 0.01% 1107
2015
Q2 		– Sell
-10,000
Closed -$742K – 3557
2015
Q1 		$742K Buy
+10,000
New +$706K ﹤0.01% 1201
2014
Q4 		– Sell
-47,200
Closed -$2.14M – 2443
2014
Q3 		$2.14M Buy
47,200
+17,200
+57% +$719K 0.01% 702
2014
Q2 		$1.24M Sell
30,000
-5,000
-14% -$258K 0.01% 815
2014
Q1 		$2.42M Buy
+35,000
New +$2.57M 0.02% 545
2013
Q4 		– Sell
-36,000
Closed -$2.19M – 2289
2013
Q3 		$2.19M Buy
+36,000
New +$2.55M 0.02% 563

Other funds holding CLVS

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Jefferies Group's CLVS Position: Q4 2021 in Review

Jefferies Group sold out of Clovis Oncology, Inc. (CLVS) in Q4 2021, closing a stake of 100,000 shares — an estimated $446K sold.

Jefferies Group first reported a position in CLVS in Q3 2013 and held it in 24 quarters. The position peaked at $2.39M in Q1 2014. 153 funds tracked by Wall St. Rank hold CLVS as of Q4 2021.

  • Jefferies Group reported no remaining Clovis Oncology, Inc. position as of Q4 2021 after selling out during the quarter.
  • Jefferies Group sold 100,000 Clovis Oncology, Inc. shares in Q4 2021, an estimated $446K.
  • Jefferies Group first reported a position in Clovis Oncology, Inc. in Q3 2013 and held it in 24 quarters.
  • Jefferies Group's Clovis Oncology, Inc. position peaked at $2.39M in Q1 2014.
  • 153 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2021.

Based on Jefferies Group's 13F filing for Q4 2021, filed 14 Feb 2022.